GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » FCF Yield %

Cormedix (Cormedix) FCF Yield % : -13.63 (As of May. 12, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cormedix FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cormedix's Trailing 12-Month Free Cash Flow is $-38.74 Mil, and Market Cap is $284.25 Mil. Therefore, Cormedix's FCF Yield % for today is -13.63%.

The historical rank and industry rank for Cormedix's FCF Yield % or its related term are showing as below:

CRMD' s FCF Yield % Range Over the Past 10 Years
Min: -236.21   Med: -14.26   Max: -3.34
Current: -13.63


During the past 13 years, the highest FCF Yield % of Cormedix was -3.34%. The lowest was -236.21%. And the median was -14.26%.

CRMD's FCF Yield % is ranked better than
51.29% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs CRMD: -13.63

Cormedix's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Cormedix FCF Yield % Historical Data

The historical data trend for Cormedix's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix FCF Yield % Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.08 -8.86 -13.03 -13.60 -18.75

Cormedix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.91 -22.60 -18.89 -17.17 -21.38

Competitive Comparison of Cormedix's FCF Yield %

For the Biotechnology subindustry, Cormedix's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cormedix's FCF Yield % falls into.



Cormedix FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cormedix's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-38.736 / 206.568008
=-18.75%

Cormedix's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-11.042 * 4 / 206.568008
=-21.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cormedix FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cormedix FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cormedix's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (Cormedix) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.
Executives
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry officer: Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco director, officer: Chief Executive Officer 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan director C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa director MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart director 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione director ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David officer: EVP, Chief Financial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson officer: EVP, Head of Clinical Ops. 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel officer: EVP, Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan director 44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz director SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan director 700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L. officer: Exec VP of Tech Operations C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch director, officer: Chief Executive Officer 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921